In response, the mechanism of action of the two drugs may target the activation of MAPK/ERK and NF-κB pathways, inhibit the expression of proliferation and invasion proteins in EMs rats, and ultimately, effectively inhibit the growth, proliferation, migration, and invasion of ectopic lesions of EMs to achieve the purpose of treating EMs. Here, NFKB1 is linked to eosinophilia-myalgia syndrome.